The @CovidAnalysis Ivermectin Meta-Analysis—Probability Ivermectin Not Effective Against COVID-19 One in One Trillion!

The @CovidAnalysis Ivermectin Meta-Analysis—Probability Ivermectin Not Effective Against COVID-19 One in One Trillion! TrialsiteN

TrialSite follows a group of brilliant researchers and scientists known as @CovidAnalysis that don’t like the limelight but do like to contribute back to society during this pandemic. Originating a website that tracks Ivermectin and other clinical trials associated with COVID-19 investigational therapies, the scholars and scientists employ their skills and experience to maintain a running tally of Ivermectin-based studies targeting COVID-19. Their takeaway after a real-time meta-analysis of 40 studies now: “Ivermectin is effective for COVID-19.”  

The anonymous group behind this website reports that 100% of the 40 studies included in their meta-analysis to date report positive effects. Overall, their data points to strong efficacy (reduction of 81% and prophylactic impact totaling a reduction of 89%). While the drug appears to impact mortality in a substantial manner, revealing 78% less mortality in the Ivermectin cohorts in these studies from around the world. Note that among the 20 randomized controlled trials (RCTs), 100% of them report positive effect with an estimated reduction of COVID-19 by 72%–see the link for the statistics as their team does a masterful job presenting all of this in a convenient, easy to ready format. One statement puts all of this in some sort of perspective as based on the study data thus far, the probability that the economical widely used drug is ineffective as a treatment targeting COVID is essentially 1 in 1 trillion.

In summary, to date there are now 40 Ivermectin studies involving 288 scientists and 14,717 patients. For more on @CovidAnalysis, see their FAQ

Call to Action: Check out the website and support this impressive group’s work. World Health Organization, National Institutes of Health, U.S. Food and Drug Administration (FDA)—check it out.